CA2172624A1 - Controlled release potassium dosage form - Google Patents

Controlled release potassium dosage form

Info

Publication number
CA2172624A1
CA2172624A1 CA002172624A CA2172624A CA2172624A1 CA 2172624 A1 CA2172624 A1 CA 2172624A1 CA 002172624 A CA002172624 A CA 002172624A CA 2172624 A CA2172624 A CA 2172624A CA 2172624 A1 CA2172624 A1 CA 2172624A1
Authority
CA
Canada
Prior art keywords
dosage unit
micropellets
unit according
coating
ethylcellulose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002172624A
Other languages
English (en)
French (fr)
Inventor
Chih-Ming Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Andrx Pharmaceuticals LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2172624A1 publication Critical patent/CA2172624A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
CA002172624A 1993-10-04 1994-09-23 Controlled release potassium dosage form Abandoned CA2172624A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/131,118 1993-10-04
US08/131,118 US5397574A (en) 1993-10-04 1993-10-04 Controlled release potassium dosage form

Publications (1)

Publication Number Publication Date
CA2172624A1 true CA2172624A1 (en) 1995-04-13

Family

ID=22447956

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002172624A Abandoned CA2172624A1 (en) 1993-10-04 1994-09-23 Controlled release potassium dosage form

Country Status (9)

Country Link
US (1) US5397574A (enExample)
EP (1) EP0804172B1 (enExample)
JP (1) JPH09510430A (enExample)
AT (1) ATE211649T1 (enExample)
AU (1) AU678858B2 (enExample)
CA (1) CA2172624A1 (enExample)
DE (1) DE69429632T2 (enExample)
NZ (1) NZ274646A (enExample)
WO (1) WO1995009617A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840329A (en) * 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
HU221435B (en) * 1998-02-20 2002-10-28 Egyt Gyogyszervegyeszeti Gyar Pellet-based pharmaceutical composition of controlled release with high content of potassium-chloride, and process for it's production
WO2001043725A1 (en) * 1999-12-16 2001-06-21 Eurand America, Inc. Controlled release kci tablet formulations
AU2002313628A1 (en) * 2001-05-22 2002-12-03 Euro-Celtique Tamper resistant oral dosage form
US6837696B2 (en) * 2001-09-28 2005-01-04 Mcneil-Ppc, Inc. Apparatus for manufacturing dosage forms
MXPA04002973A (es) * 2001-09-28 2005-06-20 Johnson & Johnson Formas de dosis de liberacion modificada.
US6780437B2 (en) * 2001-10-23 2004-08-24 Upsher-Smith Laboratories, Inc. Coated potassium chloride granules and tablets
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US6635675B2 (en) 2001-11-05 2003-10-21 Cypress Bioscience, Inc. Method of treating chronic fatigue syndrome
PT1485078E (pt) * 2002-03-15 2013-01-14 Cypress Bioscience Inc Milnacipran para o tratamento do síndrome do intestino irritável
US20040156844A1 (en) * 2002-05-22 2004-08-12 Curtis Wright Tamper resistant oral dosage form
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
US20060003004A1 (en) * 2002-10-25 2006-01-05 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
AU2004207578B2 (en) * 2003-01-28 2007-06-28 Collegium Pharmaceutical, Inc. Multiparticulate compositions of milnacipran for oral administration
US7632521B2 (en) * 2003-07-15 2009-12-15 Eurand, Inc. Controlled release potassium chloride tablets
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US8440695B2 (en) * 2005-11-09 2013-05-14 St Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
US8124598B2 (en) * 2006-09-14 2012-02-28 Sharon Sageman 7-keto DHEA for psychiatric use
US20100160274A1 (en) * 2007-09-07 2010-06-24 Sharon Sageman 7-KETO DHEA for Psychiatric Use
US20090181094A1 (en) * 2008-01-15 2009-07-16 Eric Yueh-Lang Sheu Molecular Cage for Sustained Release Control of Pharmaceutical and Cosmetic Agents
MX2011001384A (es) 2008-08-06 2011-09-27 Gosforth Ct Holdings Pty Ltd Composiciones y metodos para tratar trastornos psiquiatricos.
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
US20150133516A1 (en) 2013-11-13 2015-05-14 Brian K. Adams Methods and Compositions for Treating ADHD
CN107920995A (zh) 2015-07-02 2018-04-17 路易斯威尔大学研究基金会 用于递送miRNA的源自可食用植物的微囊泡组合物和用于治疗癌症的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL241476A (enExample) * 1958-07-24
DK152744C (da) * 1982-08-13 1988-10-31 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk peroralt polydepotpraeparat
IT1191050B (it) * 1982-10-27 1988-02-24 Pietro Tommaso Tessitore 2(1-alchil-5-nitro)-imidazolil-1-(2-idrossi-5-alchil)-fenil-carbinoli,loro metodo di preparazione e composizioni farmaceutiche che li contengono
JPS61151109A (ja) * 1984-12-26 1986-07-09 Lion Corp 毛髪化粧料組成物
JPS61171413A (ja) * 1985-01-17 1986-08-02 Pola Chem Ind Inc 養毛料
IE59066B1 (en) * 1985-02-19 1993-12-15 Key Pharma Controlled release potassium chloride
CA1270765A (en) * 1985-02-19 1990-06-26 Charles Hsiao Controlled release potassium chloride
CH666405A5 (de) * 1985-06-24 1988-07-29 Ciba Geigy Ag Feste, haltbare darreichungsformen mit elastischem filmueberzug.
JPS62175417A (ja) * 1986-01-27 1987-08-01 Kanebo Ltd 養毛化粧料
JPS6396106A (ja) * 1986-10-11 1988-04-27 Shiseido Co Ltd 化粧料
US4786503A (en) * 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
US5035898A (en) * 1987-11-27 1991-07-30 Schering Corporation Potassium/magnesium supplement
IE60383B1 (en) * 1988-05-27 1994-07-13 Elan Corp Plc Controlled release pharmaceutical formulation
JPH02111710A (ja) * 1988-10-20 1990-04-24 Akio Fujikawa 化粧料組成物
JPH03206021A (ja) * 1990-01-08 1991-09-09 Kanebo Ltd 養毛化粧料
JP2969866B2 (ja) * 1990-08-29 1999-11-02 大正製薬株式会社 発毛剤
JPH04308523A (ja) * 1991-04-04 1992-10-30 Kanebo Ltd 養毛化粧料
US5200195A (en) * 1991-12-06 1993-04-06 Alza Corporation Process for improving dosage form delivery kinetics
US5260069A (en) * 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system

Also Published As

Publication number Publication date
ATE211649T1 (de) 2002-01-15
JPH09510430A (ja) 1997-10-21
EP0804172A1 (en) 1997-11-05
AU678858B2 (en) 1997-06-12
DE69429632T2 (de) 2002-11-14
US5397574A (en) 1995-03-14
NZ274646A (en) 1997-02-24
EP0804172A4 (enExample) 1997-11-05
AU7875794A (en) 1995-05-01
DE69429632D1 (de) 2002-02-14
EP0804172B1 (en) 2002-01-09
WO1995009617A1 (en) 1995-04-13

Similar Documents

Publication Publication Date Title
EP0804172B1 (en) Controlled release potassium dosage form
KR880001753B1 (ko) 브롬헥신 서방출성 제형의 제조방법
JP4779082B2 (ja) 減少された乱用潜在性を有する薬物製剤
US3538214A (en) Controlled release medicinal tablets
US4427648A (en) Dipyridamole-containing pharmaceutical form
DE69205971T2 (de) Orale dosierungsform mit verzögerter wirkstoffabgabe für die behandlung von intestinalen krankheiten.
US5505962A (en) Controlled release pharmaceutical formulation
JPS6116368B2 (enExample)
US20050025825A1 (en) Tranexamic acid formulations with reduced adverse effects
JPH05112445A (ja) 作用開始を速くし潜在特性を増加させる移送システム
EP0211946B1 (en) Controlled release potassium chloride
JP2012514623A (ja) １またはそれ以上のフマル酸エステルを含む医薬組成物
US5589190A (en) Sustained-release compositions of alfuzosin hydrochloride
DE3232873A1 (de) Pharmazeutisches praeparat
KR20040032918A (ko) 팽창 가능한 위 정지 장치
US20030099710A1 (en) Granule modulating hydrogel system
KR20080041669A (ko) 매일 단일 투여량 형태로 투여하기에 적합한 구안파신의약학적 제형물/조성물
US4954349A (en) Oral magnesium and potassium compositions and use
US4863743A (en) Controlled release potassium chloride
CN101636153A (zh) 时间特异性延迟/脉冲释放剂型
AU619481B2 (en) Oral magnesium and potassium compositions and use
WO2001049269A1 (en) Sustained-releasing anthelmintic compositions comprising praziquantel
EA007571B1 (ru) Микрокапсулы для отсроченного и регулируемого высвобождения периндоприла
CN106466302B (zh) 口服氯化钾缓释片及其制备方法
US20040228918A1 (en) Granule modulating hydrogel system

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued